Key findings from the Phase 2 trial included: Dose-dependent weight loss , with greater reductions observed at higher doses Significant improvements in waist circumference , blood pressure , and lipid profiles Reductions in fasting glucose and insulin resistance markers, though the clinical significance of these findings in people with type 2 diabetes requires further investigation Weight loss appeared to continue throughout the 48-week period without a clear plateau at the highest doses Whilst these results are encouraging, it is important to contextualise them appropriately
The single strongest predictor is the extent of the weight loss
Novo has also been pushing new formats and pricing as competition grows, including oral Wegovy options that could make the category easier to distribute and potentially easier to budget
But certainly, if a child is obese, they can go on the drug with very, very careful supervision by a pediatrician as well as a specialist." Echoing that sentiment, Levine said that "children and teenagers see celebrities and influencers promoting Ozempic as an easy and fast weight-loss solution, and they view it as healthy
Dermatologist tip: Glycolic acid increases your skins sensitivity to the sun